ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Monday, November 13, 2023

2:00PM-3:30PM: Abstract Number: 1621

Maxillofacial MRI Augments Detection of Non-CNS Abnormalities in Pediatric Craniofacial Scleroderma

Abstracts: Pediatric Rheumatology – Clinical II: Connective Tissue Disease

2:00PM-3:30PM: Abstract Number: 1592

Memantine Attenuates the Development of Osteoarthritis by Blocking NMDA Receptor Mediated Calcium Overload and Chondrocyte Senescence

Abstracts: Osteoarthritis & Joint Biology – Basic Science

2:00PM-3:30PM: Abstract Number: 1627

Methotrexate Use Associates with Ischemic Cardiovascular Risk Reduction in Males but Not Females with Rheumatoid Arthritis

Abstracts: RA – Diagnosis, Manifestations, & Outcomes II: Comorbidities

2:00PM-3:30PM: Abstract Number: 1611

Mitochondrial Structural Alterations in Fibromyalgia – A Pilot Electron Microscopy Study

Abstracts: Fibromyalgia & Other Clinical Pain Syndromes

2:00PM-3:30PM: Abstract Number: 1587

Mitochondrial Z-DNA and ZBP1 Drive Autoimmune Photosensitivity

Abstracts: Innate Immunity

2:00PM-3:30PM: Abstract Number: 1588

Monocyte-derived Macrophages Accumulate in the Lungs in anti-MDA5+ Dermatomyositis with RP-ILD: Proinflammatory and Profibrotic Phenotype Revealed by Single-cell RNA Sequencing

Abstracts: Innate Immunity

2:00PM-3:30PM: Abstract Number: 1622

Myositis-associated Autoantibodies in Juvenile Myositis Are Associated with Severe Disease Features and Mortality

Abstracts: Pediatric Rheumatology – Clinical II: Connective Tissue Disease

2:00PM-3:30PM: Abstract Number: 1602

NADPH Oxidase Exerts a B Cell-intrinsic Contribution to Lupus Risk by Modulating Endosomal Toll-like Receptor (TLR) Signals

Abstracts: SLE – Etiology & Pathogenesis

2:00PM-3:30PM: Abstract Number: 1656

Nothing About Us Without Us: Top 10 Research Priorities from Patients – A James Lind Alliance Project for Public and Patient Involvement (PPI)

Abstracts: Interprofessional Exemplary

2:00PM-3:30PM: Abstract Number: 1650

Optic Nerve Sheath Measurement as a Disease Activity Biomarker in Giant Cell Arteritis

Abstracts: Vasculitis – Non-ANCA-Associated & Related Disorders I: Imaging

2:00PM-3:30PM: Abstract Number: 1594

Oral Delivery of Δ9-Tetrahydrocannabinol Provides Symptom and Disease Modification in a Mouse Model of Knee Osteoarthritis

Abstracts: Osteoarthritis & Joint Biology – Basic Science

2:00PM-3:30PM: Abstract Number: 1630

Patient-Reported Fatigue Associated with Joint Histopathology in Rheumatoid Arthritis

Abstracts: RA – Diagnosis, Manifestations, & Outcomes II: Comorbidities

2:00PM-3:30PM: Abstract Number: 1629

Persons with Rheumatoid Arthritis and Long COVID Had Worse Pre-COVID RA Symptoms and Worse Non-RA Symptoms, as Well as Higher Rates of Fibromyalgia Compared with COVID Infected Long COVID Negative

Abstracts: RA – Diagnosis, Manifestations, & Outcomes II: Comorbidities

2:00PM-3:30PM: Abstract Number: 1595

Pharmacological Modulation of Krüppel-like Factor 4 Reduces the Severity of Experimental Osteoarthritis via Tissue Protection and Regeneration

Abstracts: Osteoarthritis & Joint Biology – Basic Science

2:00PM-3:30PM: Abstract Number: 1608

Plasma Proteomic Profiling in Antiphospholipid Antibody-positive Patients with Different Clinical Phenotypes: Results from the Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Registry

Abstracts: Antiphospholipid Syndrome

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].